Craig Portell is an Oncology physician affiliated with University of Virginia Health System. OpenAlex indexes 193 publications with 3,267 citations (h-index 29); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1240 Lee St
Charlottesville, VA 229080817
Telephone
434-924-9333Provider last certified this registry record 9 Aug 2023.
Clinical trials
- Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
- Genentech USA, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.1%Kinase inhibitor54%Calquence36%Imbruvica35%Brukinsa29%Part D<11 patientsBCL-2 Inhibitor3%Venclexta100%Part D<11 patientsMetabolism & gastrointestinal
15%Serotonin-3 Receptor Antagonist5.8%Ondansetron Hcl100%Part D≥14 patientsCorticosteroid5.5%Prednisone100%Part D<11 patients+ 1 more class in this area
Dermatology
10.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.5%Acyclovir100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).
University of Virginia
FY2025$808,684R01FD006814
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology
2025 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
New England Journal of Medicine
2024 - Outcomes of patients with <scp>limited‐stage</scp> plasmablastic lymphoma: A <scp>multi‐institutional</scp> retrospective study
American Journal of Hematology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Todd Villines, MD
University of Virginia Health System
Benjamin Purow, MD
University of Virginia Health System
Linda Duska, MD
University of Virginia Health System
Kenneth Bilchick, MD
University of Virginia Health System
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”